Business
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid
About this update from Apellis Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and product-specific J-code (J2781) for SYFOVRE® (pegcetacoplan injection), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration. The J-code for SYFOVRE will become effective on October 1, 2023. \"Until SYFOVRE, patients had nothing to slow the progression of this relentless and irreversible disease,” said Adam Townsend, chief commercial officer, Apellis. “The permanent J-code is a significant milestone that will help ensure accurate and efficient reimbursement of SYFOVRE in all treatment settings, building on our goal of bringing this important treatment to GA patients in need.” J-codes are permanent reimbursement codes used by government payers and commercial insurers to facilitate billing of Medicare Part B treatments, which must be administered by a healthcare professional. J-codes simplify and streamline the billing and reimbursement processes, allowing for efficient claims processing. The permanent J-code has been published by CMS here. About Geographic Atrophy (GA)Geographic atrophy (GA) is an advanced form of age-related macular degeneration and a leading cause of blindness worldwide, impacting more than one million Americans and five million people worldwide.1,2 It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision. The vision loss caused by GA severely impairs independence and quality of life by making it difficult to participate in daily activities. On average, it takes only 2.5 years for GA lesions to start impacting the fovea, which is responsible for central vision.3 About SYFOVRE® (pegcetacoplan injection) SYFOVRE® (pegcetacoplan injection) is the first-ever treatment for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system. SYFOVRE is approved in the United States for the treatment of GA secondary to age-related macular degeneration. U.S. Important Safety Information for SYFOVRE® (pegcetacoplan injection) CONTRAINDICATIONS SYFOVRE is contraindicated in patients with ocular or periocular infection...